Clinical trial
An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Patients With Metastatic Renal Cell Carcinoma That is Progressive Following or During Immunotherapy
NCT00106613 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Patients With Metastatic Renal Cell Carcinoma That is Progressive Following or During Immunotherapy
- Lead sponsor
- Celgene
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 1, 2003
- Completion date
- August 1, 2004
- Enrollment
- 30 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.